Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $165 | $157 | $148 | $159 |
| % Growth | 5% | 6% | -6.7% | – |
| Cost of Goods Sold | $78 | $77 | $75 | $95 |
| Gross Profit | $87 | $80 | $74 | $64 |
| % Margin | 53% | 50.8% | 49.7% | 40.3% |
| R&D Expenses | $20 | $14 | $14 | $16 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $58 | $50 | $55 | $56 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Expenses | $79 | $64 | $69 | $72 |
| Operating Income | $9 | $16 | $5 | -$8 |
| % Margin | 5.3% | 10.1% | 3.2% | -5% |
| Other Income/Exp. Net | $16 | $17 | $13 | $13 |
| Pre-Tax Income | $26 | $33 | $18 | $5 |
| Tax Expense | $11 | $13 | $9 | -$5 |
| Net Income | $15 | $20 | $9 | $10 |
| % Margin | 9.1% | 12.9% | 5.8% | 6.3% |
| EPS | 0.4 | 0.54 | 0.23 | 0.27 |
| % Growth | -25.9% | 134.8% | -14.8% | – |
| EPS Diluted | 0.4 | 0.54 | 0.23 | 0.27 |
| Weighted Avg Shares Out | 38 | 38 | 38 | 38 |
| Weighted Avg Shares Out Dil | 38 | 38 | 38 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16 | $15 | $14 | $11 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $8 | $7 | $8 | $8 |
| EBITDA | $18 | $23 | $14 | $6 |
| % Margin | 11% | 14.7% | 9.4% | 3.9% |